Table 1.
Demographic characteristics of inflammatory bowel disease (IBD) patients in Gil Medical Center (GMC) and the Korean common data model (K-CDM).
| Derivation and Internal Validation Set from GMC Database (n = 1299) | External Validation Set from K-CDM Database (n = 1987) | |
|---|---|---|
| Demographic features and follow-up | ||
| Duration of follow-up, weeks | 152.0 ± 157.6 | 183.0 ± 198.6 |
| Males, n (%) | 782 (60.2%) | 1310 (65.9%) |
| Age, years | 44.3 ± 19.3 | 45.8 ± 17.7 |
| IBD subtype | ||
| Ulcerative colitis | 763 (58.7%) | 1060 (53.3%) |
| Crohn’s disease | 536 (41.3%) | 927 (46.7%) |
| Disease behavior at diagnosis | ||
| Age at diagnosis | 36.5 ± 18.3 | 36.7 ± 16.7 |
| Phenotype of IBD | ||
| Systemic steroid use at diagnosis, n (%) | 712 (54.8%) | 733 (36.9%) |
| IBD related outcome (biologic agent) | ||
| Commencement of Biologic agents, n (%) | 135 (10.4%) | 146 (7.3%) |
| Ulcerative colitis, n | 65 | 70 |
| Crohn’s disease, n | 70 | 76 |
| Duration of disease before the first biologic agent use (mean ±SD)(week) | 117.3 ± 18.5 | 232.5 ± 22.2 |
| Laboratory data(at first visit to hospital with symptom) | ||
| Hemoglobin (g/dL) | 12.9 ± 2.2 | 13.1 ± 2.1 |
| Hematocrit (%) | 38.7 ± 5.6 | 38.9 ± 5.6 |
| White blood cell count (103/㎕) | 8.3 ± 3.6 | 8.1 ± 3.5 |
| Serum total bilirubin (mg/dL) | 0.7 ± 0.5 | 0.7 ± 0.5 |
| Serum protein (g/dL) | 7.8 ± 15.3 | 8.3 ± 19.9 |
| Serum albumin (g/dL) | 4.1 ± 0.6 | 5.1 ± 0.5 |
| Serum BUN (mg/dL) | 12.7 ± 5.9 | 12.9 ± 5.0 |
| Serum creatinine (mg/dL) | 1.0 ± 3.7 | 1.0 ± 4.8 |
| Serum hsCRP (mg/L) † | 2.1 ± 3.8 | 1.8 ± 3.6 |
| Serum uric acid (mg/dL) | 5.2 ± 1.6 | 4.9 ± 1.5 |
| Serum cholesterol (mg/dL) | 161.8 ± 41.0 | 170.3 ± 42.0 |
Abbreviation: IBD, inflammatory bowel disease; GMC, Gil medical center; K-CDM, Korean common data model network; IQR, interquartile range; SD, standard deviation; BUN, blood urea nitrogen; CRP, C-reactive protein; † The reference range for hsCRP was 0–0.5 mg/L.